VistaGen Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.24	Vistagen to Present at the Stifel 2024 Healthcare Conference (Businesswire)
07.11.24	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Businesswire)
05.11.24	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Businesswire)
01.11.24	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Businesswire)
09.10.24	Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day (Businesswire)
23.09.24	Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Businesswire)
13.08.24	Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update (Businesswire)
06.08.24	Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 (Businesswire)
09.07.24	Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine (Businesswire)
27.06.24	Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year (Businesswire)
11.06.24	Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (Businesswire)
07.06.24	Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 (Businesswire)
29.05.24	Vistagen to Present at the Jefferies Global Healthcare Conference (Businesswire)
23.05.24	Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference (Businesswire)
07.05.24	Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference (Businesswire)
25.04.24	Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue (Businesswire)
09.04.24	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Businesswire)
01.04.24	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Businesswire)
11.03.24	Vistagen to Present at Stifel 2024 Virtual CNS Days (Businesswire)
28.02.24	Vistagen to Present at TD Cowen 44th Annual Health Care Conference (Businesswire)
13.02.24	Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update (Businesswire)
06.02.24	Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 (Businesswire)
27.12.23	Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain (Businesswire)
07.12.23	Pre-market Movers: MLGO, ZVSA, CXM, WVE, AAMC… (RTTNews)
09.11.23	Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results (Businesswire)
08.11.23	Vistagen to Present at Stifel 2023 Healthcare Conference (Businesswire)
07.11.23	Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences (Businesswire)
06.11.23	Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023 (Businesswire)
05.10.23	Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (Businesswire)
02.10.23	Vistagen Announces Pricing of $100 Million Underwritten Offering (Businesswire)
12.09.23	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (Businesswire)
05.09.23	Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan (Businesswire)
22.08.23	Vistagen Appoints Cindy Anderson as Chief Financial Officer (Businesswire)
10.08.23	Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results (Businesswire)
10.08.23	Pre-market Movers: CPRI, ORGN, ORGO, RWOD, APP… (RTTNews)
08.08.23	Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023 (Businesswire)
07.08.23	Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (Businesswire)
17.07.23	Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain (Businesswire)
13.07.23	Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease (Businesswire)
28.06.23	Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results (Businesswire)
27.06.23	Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023 (Businesswire)
23.06.23	Vistagen Regains Full Compliance with Nasdaq Listing Requirements (Businesswire)
21.06.23	Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder (Businesswire)
16.06.23	Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest (Businesswire)
13.06.23	Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine (Businesswire)
07.06.23	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes (Businesswire)
06.06.23	Vistagen to Present at Jefferies 2023 Global Healthcare Conference (Businesswire)
06.06.23	Vistagen Announces Stockholder-Approved Reverse Stock Split (Businesswire)
01.06.23	Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Businesswire)
30.05.23	Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu VistaGen Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten